Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Epilepsy
← New Search

Epilepsy

Educational clinical summary of Epilepsy for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Overview

  • Definition: Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures resulting from abnormal, excessive, or synchronous neuronal activity in the brain. A diagnosis of epilepsy is typically made after at least two unprovoked seizures occurring more than 24 hours apart, or one unprovoked seizure and a probability of further seizures similar to the general recurrence risk after two unprovoked seizures (e.g., structural brain lesion, epileptiform EEG).
  • Epidemiology:
    • Incidence: Approximately 40-70 per 100,000 person-years globally, with higher rates in low- and middle-income countries.
    • Prevalence: Affects about 1% of the global population (around 50 million people).
    • Age: Bimodal distribution, with highest incidence in early childhood and in older adults (>60 years).
    • Sex: Slightly higher incidence in males, though varies by seizure type and etiology.
    • Mortality: People with epilepsy have a two to three times higher risk of premature death compared to the general population, largely due to SUDEP (Sudden Unexpected Death in Epilepsy), status epilepticus, and accidents related to seizures.
  • Classification: The International League Against Epilepsy (ILAE) 2017 classification categorizes seizures and epilepsies.
    • Seizure Types (based on onset):
      • Focal onset: Originate in one hemisphere. Can be aware (formerly simple partial) or impaired awareness (formerly complex partial). May evolve to bilateral tonic-clonic seizures.
      • Generalized onset: Originate simultaneously in both hemispheres. Includes tonic-clonic, absence, myoclonic, atonic, tonic, and clonic seizures.
      • Unknown onset: When onset cannot be determined (e.g., witnessed alone, nocturnal).
    • Epilepsy Types (based on etiology, semiology, and EEG):
      • Focal epilepsy: Seizures originate in a specific brain region.
      • Generalized epilepsy: Seizures originate in and rapidly engage bilaterally distributed networks.
      • Combined generalized and focal epilepsy: Patients experience both seizure types.
      • Unknown epilepsy type: When the above cannot be determined.
    • Etiologies (can be integrated into epilepsy type heading):
      • Structural: Due to macroscopic brain lesions (e.g., stroke, tumor, malformation).
      • Genetic: Due to known or presumed genetic disorders (e.g., Dravet syndrome, SCN1A mutations).
      • Infectious: Post-infection (e.g., neurocysticercosis, viral encephalitis).
      • Metabolic: Due to metabolic derangements (e.g., porphyria, mitochondrial disorders).
      • Immune: Due to autoimmune processes (e.g., LGI1 encephalitis).
      • Unknown: When the cause cannot be identified.

Pathophysiology

  • Mechanism: Epilepsy arises from an imbalance between excitatory and inhibitory neurotransmission in the brain, leading to hypersynchronous neuronal firing.
    • Excitatory Neurotransmission: Primarily mediated by glutamate via AMPA and NMDA receptors. Excessive activation or reduced clearance of glutamate can lead to hyperexcitability.
    • Inhibitory Neurotransmission: Primarily mediated by GABA via GABA-A and GABA-B receptors. Deficient GABAergic inhibition (e.g., loss of GABAergic interneurons, receptor dysfunction) can lower seizure threshold.
    • Cellular Mechanisms:
      • Ion Channel Dysfunction (Channelopathies): Mutations in voltage-gated sodium, potassium, calcium, and chloride channels are common genetic causes, altering neuronal excitability.
      • Synaptic Plasticity: Changes in synaptic strength and structure can contribute to epileptogenesis.
      • Network Hyperexcitability: Aberrant neuronal networks develop, facilitating seizure propagation.
      • Astrocytic Dysfunction: Glial cells play a critical role in maintaining ion homeostasis and neurotransmitter clearance (especially glutamate); dysfunction can contribute to epileptogenesis.
      • Inflammation: Neuroinflammation can induce neuronal hyperexcitability.
  • Risk Factors:
    • Genetic Predisposition: Family history of epilepsy, specific genetic syndromes.
    • Brain Injury: Traumatic Brain Injury (TBI), especially moderate to severe.
    • Stroke: Particularly hemorrhagic strokes and cortical infarcts. Risk highest after a cortical stroke, affecting up to 10% of survivors.
    • Brain Infections: Meningitis, encephalitis, neurocysticercosis, cerebral malaria, HIV.
    • Brain Tumors: Both primary and metastatic lesions.
    • Neurodegenerative Diseases: Alzheimer's disease, dementia.
    • Developmental Brain Abnormalities: Cortical dysplasia, hippocampal sclerosis, tuberous sclerosis.
    • Perinatal Injuries: Hypoxic-ischemic encephalopathy, intracranial hemorrhage.
    • Substance Abuse: Alcohol withdrawal, stimulant abuse.
    • Fever (in children): Febrile seizures, while often benign, a small percentage can lead to later epilepsy development, especially if prolonged or focal.
  • Protective Factors:
    • Early and effective treatment of underlying brain conditions: Prompt management of brain infections, tumors, or TBI may reduce the risk of epileptogenesis.
    • Vaccination: Against common causes of encephalitis/meningitis.
    • Avoidance of head trauma: Use of helmets, seatbelts.
    • Controlled management of fevers in children: Though largely unproven for prevention of epilepsy, proper management of febrile seizures is standard care.

Clinical Presentation

Signs and Symptoms

  • Cardinal Features:
    • Recurrent, unprovoked seizures: The hallmark of epilepsy. Patient may describe a range of experiences depending on seizure type.
    • Post-ictal confusion/fatigue: Common after generalized tonic-clonic seizures and focal seizures with impaired awareness.
    • Automatisms: Repetitive, non-purposeful movements (e.g., lip smacking, fumbling, chewing, repeating phrases) seen in focal seizures with impaired awareness.
    • Aura: A subjective sensation preceding a seizure, representing the focal onset of the seizure (e.g., déja vu, fear, specific smells/tastes, tingling, visual distortion).
  • Early Signs (of impending seizure or during aura):
    • May include a specific aura as described above.
    • Prodromal symptoms (hours to days prior): mood changes, irritability, headache, lethargy (less specific).
  • Advanced Signs (during a seizure):
    • Generalized Tonic-Clonic (GTC): Loss of consciousness, body stiffening (tonic phase), rhythmic jerking (clonic phase), tongue biting, incontinence.
    • Absence: Staring spells, brief loss of awareness (seconds), often with subtle automatisms (eyelid fluttering, lip smacking), abrupt onset and offset. More common in children.
    • Focal (aware): Localized motor (jerking of a limb), sensory (tingling, numbness), autonomic (epigastric rising sensation, flushing), or psychic (fear, déja vu) phenomena without loss of awareness.
    • Focal (impaired awareness): Staring, automatisms, inability to respond, confusion during and after the event.
    • Myoclonic: Brief, shock-like jerks of a muscle or group of muscles, often in the morning, without loss of consciousness.
    • Atonic: Sudden loss of muscle tone, causing falls ("drop attacks"), brief.
  • Atypical Presentations:
    • Non-epileptic seizures (NES) / Psychogenic non-epileptic seizures (PNES): Clinically resemble epileptic seizures but are not associated with abnormal electrical brain activity. Often triggered by psychological stress. Differentiated by video-EEG.
    • Status Epilepticus (SE): Prolonged seizure activity (typically >5 minutes) or recurrent seizures without full recovery of consciousness between them. A medical emergency.
    • Sudden Unexpected Death in Epilepsy (SUDEP): The sudden, unexpected, non-traumatic, and non-drowning death in patients with epilepsy, with or without evidence of a preceding seizure, and without a toxicological or anatomical cause of death found postmortem. Common in patients with refractory GTC seizures.

Physical Examination

  • Inspection:
    • General: Evidence of recent trauma (head lacerations, bruises, tongue bite marks, particularly lateral), incontinence.
    • Neurological: Post-ictal deficits such as Todd's paralysis (transient localized weakness post-seizure), altered mental status, fixed pupils (during seizure). Baseline neurological exam may be completely normal between seizures. Look for subtle neurological deficits that might point to a structural lesion (e.g., mild hemiparesis, visual field defect).
  • Palpation: Not typically diagnostic for epilepsy itself. May be used to assess for skull deformities or tenderness if a head injury is suspected.
  • Special Tests:
    • Fundoscopy: To rule out papilledema (suggesting increased intracranial pressure from a mass lesion), or signs of neurocutaneous syndromes (e.g., retinal phakomas in tuberous sclerosis).
    • Detailed Neurological Exam: Essential between seizures to identify any focal deficits pointing to underlying structural pathology or diffuse encephalopathy. This includes motor, sensory, reflex, coordination, and cranial nerve examination.

Diagnostic Approach

History Taking

  • Key Questions:
    • Detailed seizure semiology: Witness account is crucial. What exactly happened before, during, and after the event? Was there an aura? Loss of consciousness? Motor activity (tonic, clonic, automatisms)? Duration? Post-ictal state? Any incontinence or tongue biting?
    • Frequency, duration, date of first seizure: Establishes progression and diagnosis.
    • Precipitating factors: Sleep deprivation, stress, alcohol, flashing lights (photosensitivity), menstruation, specific medications.
    • Past medical history: Head trauma, stroke, meningitis, encephalitis, febrile seizures in childhood, family history of epilepsy or neurological disorders.
    • Medications: Current medications (including over-the-counter and herbal supplements), compliance with anti-seizure medications (ASMs).
    • Developmental history: For pediatric patients.
    • Social history: Alcohol/drug use, occupation (implications for driving/safety).
  • Red Flags:
    • First seizure in adulthood: Requires thorough investigation for underlying structural or metabolic causes.
    • Focal neurological deficits in the post-ictal period (Todd's paralysis): Suggests a focal onset or underlying structural lesion.
    • Status Epilepticus: Medical emergency requiring immediate intervention.
    • History of head trauma, severe infection, or stroke: Increased risk and warrants investigation.
    • Rapidly progressive neurological decline: Suggests a progressive etiology (e.g., tumor, neurodegenerative disease).

Laboratory Tests

  • First-Line (to exclude treatable causes of seizures and mimicry):
    • Complete Blood Count (CBC): To check for infection, anemia.
    • Electrolytes: Sodium, potassium, calcium, magnesium (hypo/hypernatremia, hypocalcemia, hypomagnesemia can precipitate seizures).
    • Glucose: Hypoglycemia or hyperglycemia can trigger seizures.
    • Renal and Liver Function Tests: Baseline for ASM selection and to check for organ dysfunction affecting drug metabolism.
    • Toxicology Screen (urine/blood): To rule out drug-induced seizures (e.g., cocaine, amphetamines) or withdrawal (alcohol, benzodiazepines).
    • Serum Prolactin: Can be elevated acutely post-ictally in generalized tonic-clonic or complex partial seizures, but not reliable for differentiating epileptic from non-epileptic seizures. Obtain 10-20 minutes post-ictally for optimal utility.
  • Confirmatory (for specific etiologies or difficult cases):
    • Lumbar Puncture (CSF analysis): If infection (meningitis, encephalitis) or inflammatory/autoimmune etiology is suspected (e.g., pleocytosis, elevated protein, oligoclonal bands, specific antibody assays).
    • Genetic Testing: For suspected genetic epilepsies, especially in pediatric cases or syndromic presentations. Panels for common epilepsy genes (e.g., SCN1A, KCNQ2).
    • Autoimmune Antibody Panel: For suspected autoimmune encephalitis (e.g., Anti-LGI1, Anti-NMDA-R, Anti-GABAR-B, Anti-CASPR2).
    • Metabolic Screening: For suspected inborn errors of metabolism (e.g., amino acids, organic acids, mitochondrial studies).
  • Monitoring:
    • Therapeutic Drug Monitoring (TDM): Measurement of ASM plasma levels to guide dosing, assess compliance, identify toxicity, especially for drugs with narrow therapeutic indices (e.g., phenytoin, carbamazepine, valproate). Not routinely required for all ASMs.

Imaging

  • Recommended:
    • Magnetic Resonance Imaging (MRI) of the Brain with Epilepsy Protocol: The imaging modality of choice for evaluating structural causes of epilepsy.
      • Timing: Should be performed after a first unprovoked seizure, ideally within a few days, or certainly before starting chronic ASM treatment.
      • Protocol: High-resolution 3D sequences (e.g., T1 FSPGR/MPRAGE), T2-weighted, FLAIR, DWI, gradient echo, and ideally thin coronal slices perpendicular to the hippocampus. Contrast enhancement may be indicated if tumor, infection, or inflammatory lesion is suspected.
      • Findings: Can detect focal cortical dysplasia, hippocampal sclerosis, tumors, cavernomas, infarcts, arteriovenous malformations, and other structural lesions.
    • Electroencephalography (EEG):
      • Routine EEG: Performed after the first unprovoked seizure. Ideally awake and sleep recordings (spontaneous or induced). Lasts 20-40 minutes. May show epileptiform discharges (spikes, sharp waves, spike-and-wave complexes) or background abnormalities. A normal EEG does not rule out epilepsy.
      • Sleep-Deprived EEG: Increases yield of epileptiform activity.
      • Long-term Video-EEG Monitoring (V-EEG): Crucial for confirming epilepsy diagnosis, characterizing seizure type, localizing seizure onset zone, and differentiating epileptic seizures from PNES. Involves continuous EEG recording synchronized with video. Often inpatient.
  • Advanced (when standard imaging is unrevealing or for surgical planning):
    • Functional MRI (fMRI): For localization of eloquent cortex (e.g., language, motor areas) prior to epilepsy surgery.
    • Positron Emission Tomography (PET) Scan (FDG-PET): Interictal hypometabolism can localize seizure onset zones in focal epilepsy, particularly in patients with non-lesional MRI.
    • Single-Photon Emission Computed Tomography (SPECT) Scan: Ictal hyperperfusion and interictal hypoperfusion can help localize seizure onset zones. Requires injection of tracer during a seizure.
    • Magnetoencephalography (MEG): Detects magnetic fields produced by electrical currents in the brain, offering excellent spatial resolution for localizing epileptogenic foci, especially when combined with MRI.

Management

Acute Management

  • Immediate (0-5 minutes):
    • Protect the patient: Move away from hazards, loosen tight clothing around neck. Do NOT restrain or place anything in the mouth.
    • Time the seizure: Crucial for determining if status epilepticus.
    • Place patient in recovery position (on side) after tonic-clonic activity to prevent aspiration.
  • Stabilization (if status epilepticus, >5 minutes of continuous seizure or recurrent seizures without recovery):
    • Maintain airway, breathing, circulation (ABCs): Administer oxygen, establish IV access.
    • Administer first-line anticonvulsants (benzodiazepines):
      • Lorazepam: IV 0.1 mg/kg (up to 4 mg) at 2 mg/min, may repeat once after 5-10 minutes. Preferred due to rapid action and longer duration.
      • Diazepam: IV 0.2 mg/kg (up to 10 mg) at 5 mg/min, or rectal 0.2-0.5 mg/kg (up to 20 mg). Shorter duration of action.
      • Midazolam: IM 10 mg (adults), intranasal/buccal 0.2 mg/kg (up to 10 mg). Useful in out-of-hospital settings.
    • Assess for precipitants: Hypoglycemia (give dextrose if blood glucose <60 mg/dL), hyponatremia.
  • Emergency (if seizure continues after initial benzodiazepines):
    • Second-line anticonvulsants:
      • Fosphenytoin / Phenytoin: IV fosphenytoin 20 mg PE/kg (phenytoin equivalent) at 100-150 mg PE/min. Less cardiovascular toxicity with fosphenytoin. Max dose 1500 mg PE.
      • Levetiracetam: IV 20-60 mg/kg (up to 4500 mg) over 10-15 minutes.
      • Valproate: IV 20-40 mg/kg over 5 minutes (max 3000 mg).
      • Lacosamide: IV 200-400 mg over 15-30 minutes.
    • Refractory Status Epilepticus: If seizures persist despite two ASMs, consider continuous EEG monitoring in ICU and induction of general anesthesia with continuous infusions (midazolam, propofol, phenobarbital) to achieve burst suppression on EEG.

Chronic Management

  • Pharmacological: Anti-Seizure Medications (ASMs) are the cornerstone of chronic management. Selection depends on seizure type, epilepsy syndrome, patient comorbidities, potential side effects, and drug-drug interactions. Monotherapy is preferred initially.
    • First-line for Focal Seizures:
      • Levetiracetam: Generally well-tolerated, broad spectrum. Initial 250-500 mg BID, common target 1000-3000 mg/day BID.
      • Lamotrigine: Good for focal and generalized seizures, low cognitive side effects. Slow titration due to rash risk (start 25 mg/day, increase by 25-50 mg every 1-2 weeks). Target 100-500 mg/day. Black box warning for Stevens-Johnson Syndrome/TEN.
      • Carbamazepine: Classic for focal seizures, effective for GTC. Initial 100-200 mg BID, target 600-1200 mg/day. Requires monitoring of CBC, LFTs, and sodium. Genetic testing for HLA-B*1502 allele for severe skin reactions in Asian patients.
      • Oxcarbazepine: Derivative of carbamazepine, fewer drug interactions. Initial 150-300 mg BID, target 900-1800 mg/day. Risk of hyponatremia.
    • First-line for Generalized Seizures (including GTC, absence, myoclonic):
      • Valproate: Broad spectrum, very effective for generalized seizures. Initial 250-500 mg BID, target 1000-3000 mg/day. Significant side effects: teratogenicity (neural tube defects, developmental delay), hepatotoxicity, thrombocytopenia, weight gain, hair loss. Contraindicated in pregnancy unless no other effective treatment.
      • Levetiracetam: Effective for GTC, myoclonic.
      • Lamotrigine: Effective for GTC, absence (less so than valproate/ethosuximide).
      • Ethosuximide: First-line for absence seizures only. Initial 250 mg BID, target 500-1500 mg/day. Minimal side effects.
    • Other commonly used ASMs: Topiramate, Zonisamide, Lacosamide, Clobazam, Phenobarbital, Gabapentin, Pregabalin.
    • Discontinuation: Consider after 2-5 years seizure-free, depending on etiology, epilepsy syndrome, and EEG findings. Generally, a slow taper over several months is recommended to minimize withdrawal seizures.
  • Non-pharmacological:
    • Epilepsy Surgery: For drug-resistant focal epilepsy. Involves resection of the epileptogenic zone. Requires comprehensive pre-surgical evaluation (V-EEG, MRI, fMRI, PET, neuropsychological testing). E.g., anterior temporal lobectomy for temporal lobe epilepsy.
    • Neurostimulation:
      • Vagal Nerve Stimulation (VNS): Implanted device stimulates the vagus nerve. Adjunctive treatment for drug-resistant focal or generalized epilepsy and for those not candidates for resective surgery.
      • Responsive Neurostimulation (RNS): Implanted device detects and aborts seizures by delivering targeted electrical stimulation. Approved for focal epilepsy.
      • Deep Brain Stimulation (DBS): Electrodes implanted in specific brain regions (e.g., anterior nucleus of thalamus) for drug-resistant epilepsy.
    • Dietary Therapies:
      • Ketogenic Diet: High-fat, low-carbohydrate, adequate-protein diet. Induces ketosis. Effective in some children and adults with refractory epilepsy, especially multifocal or certain genetic epilepsies. Requires close medical and nutritional supervision.
      • Modified Atkins Diet (MAD): Less restrictive than ketogenic diet, similar mechanism.
    • Lifestyle Modifications:
      • Sleep hygiene: Avoid sleep deprivation.
      • Stress reduction: Manage stress through relaxation techniques.
      • Alcohol avoidance: Minimize or avoid alcohol, as it can lower seizure threshold.
      • Regular exercise: Benefits general health, may reduce seizure frequency.
      • Safety measures: Shower instead of bathe, use caution with heights/machinery, wear medical alert bracelet.
  • Monitoring (Chronic):
    • Regular clinical follow-ups: Assess seizure frequency, severity, side effects of ASMs, compliance.
    • Neuropsychological assessment: To screen for cognitive impairment or mood disorders (depression, anxiety), which are common comorbidities.
    • Laboratory monitoring: As indicated for specific ASMs (e.g., LFTs, CBC for carbamazepine/valproate; sodium for oxcarbazepine; vitamin D for enzyme-inducing ASMs).
    • Bone density screening: For long-term ASM users, especially enzyme-inducing ones, due to increased risk of osteoporosis.
    • Driving restrictions: Advise patients on local driving laws (e.g., usually 6 months to 1 year seizure-free period required).

Treatment Algorithms

  • First-Line:
    1. Diagnosis of epilepsy confirmed: Based on history, EEG, MRI.
    2. Classify seizure type and epilepsy syndrome: Crucial for ASM selection.
    3. Start monotherapy with appropriate ASM:
      • Focal onset: Levetiracetam, Lamotrigine, Carbamazepine, Oxcarbazepine.
      • Generalized onset (GTC): Valproate, Levetiracetam, Lamotrigine.
      • Generalized onset (Absence): Ethosuximide (first choice), Valproate (if GTC also present, or if ethosuximide fails).
      • Generalized onset (Myoclonic): Valproate, Levetiracetam.
    4. Titrate ASM to optimal dose: Achieve seizure control with minimal side effects.
  • Second-Line:
    1. If first-line ASM fails (due to lack of efficacy or intolerable side effects):
      • Try a different first-line ASM (monotherapy): If the first drug was intolerable.
      • Add a second ASM (duel therapy): If the first drug provided partial benefit but not full seizure control. Choose a drug with a different mechanism of action and favorable interaction profile.
  • Refractory Cases (Drug-Resistant Epilepsy): Defined as failure of adequate trials of two tolerated and appropriately chosen ASMs (as monotherapy or in combination) to achieve sustained seizure freedom.
    1. Re-evaluate diagnosis: Ensure correct epilepsy type and rule out PNES. Review ASM adherence.
    2. Consider alternative ASMs: Explore newer ASMs or those not yet tried.
    3. Refer to an Epilepsy Center: For comprehensive evaluation by a multidisciplinary team.
    4. Evaluate for non-pharmacological treatments:
      • Epilepsy Surgery: For eligible focal epilepsy patients.
      • Neurostimulation devices: VNS, RNS, DBS.
      • Dietary therapies: Ketogenic diet, Modified Atkins diet.

Complications

  • Common:
    • ASM side effects: Drowsiness, fatigue, dizziness, gastrointestinal upset, rash, cognitive impairments (memory, concentration), mood changes.
    • Psychiatric comorbidities: Depression and anxiety are highly prevalent (up to 50%).
    • Cognitive dysfunction: Memory, attention, and executive function deficits, can be due to epilepsy itself, ASMs, or underlying etiology.
    • Accidents and injuries: Falls, fractures, burns, drowning, due to loss of consciousness during seizures.
  • Serious:
    • Status Epilepticus: Life-threatening medical emergency, can lead to neuronal damage, permanent neurological deficits, or death.
    • Sudden Unexpected Death in Epilepsy (SUDEP): Leading cause of death in people with refractory epilepsy. Risk factors include frequent GTC seizures, younger age at epilepsy onset, male sex, not being seizure-free.
    • Teratogenicity with ASMs: Especially valproate (neural tube defects, developmental delay, congenital heart defects, orofacial clefts).
    • Rashes (e.g., Stevens-Johnson Syndrome/TEN): Associated with lamotrigine, carbamazepine, phenytoin, phenobarbital. Can be life-threatening.
    • Hepatotoxicity: Valproate, phenobarbital.
    • Aplastic Anemia / Agranulocytosis: Carbamazepine.
  • Long-term:
    • Social and vocational difficulties: Stigma, driving restrictions, challenges with employment and education.
    • Increased risk of bone disease: Osteoporosis/osteomalacia, especially with long-term enzyme-inducing ASMs (e.g., phenytoin, phenobarbital, carbamazepine).
    • Cardiovascular disease: Increased risk, potentially related to ASM effects or inflammation.

Prognosis

  • Factors affecting outcome:
    • Etiology: Symptomatic epilepsy (structural, genetic, metabolic) generally has a worse prognosis than idiopathic epilepsy.
    • Epilepsy syndrome: Some syndromes (e.g., benign rolandic epilepsy) have excellent prognosis, while others (e.g., infantile spasms, Dravet syndrome) are severe with high rates of refractory epilepsy and developmental delay.
    • Seizure type and frequency: Generalized tonic-clonic seizures and high seizure frequency are associated with poorer outcomes.
    • Response to ASMs: Most (60-70%) achieve seizure freedom with initial ASM therapy. About 30-40% develop drug-resistant epilepsy.
    • Age of onset: Childhood-onset epilepsy often has better prognosis than adult-onset, but highly variable.
    • Presence of comorbidities: Psychiatric and neurological comorbidities worsen prognosis.
  • Survival:
    • Overall mortality rate is 2-3 times higher than the general population.
    • SUDEP accounts for a significant portion of epilepsy-related deaths.
  • Quality of Life:
    • Epilepsy significantly impacts daily life activities, independence, and overall well-being.
    • Factors contributing to reduced quality of life include seizure frequency/severity, ASM side effects, psychiatric comorbidities (anxiety, depression), perceived stigma, and social isolation.
    • Achieving seizure freedom is the primary goal, but managing comorbidities and optimizing QoL are also crucial.

Prevention

  • Primary: Aimed at preventing the initial occurrence of epilepsy.
    • Head injury prevention: Helmets for sports, seatbelts in vehicles.
    • Perinatal care improvements: Reducing birth trauma, hypoxia, and preterm births.
    • Infection control: Vaccinations (e.g., measles, mumps, rubella, Hib, pneumococcal), proper hygiene to reduce meningitis/encephalitis.
    • Stroke prevention: Control of hypertension, diabetes, hyperlipidemia.
    • Prevention of substance abuse: Especially alcohol and stimulant misuse.
  • Secondary: Early detection and intervention to prevent more severe epilepsy or complications.
    • Prompt treatment of febrile seizures: While not proven to prevent epilepsy, proper management is standard and prevents other complications.
    • Early and aggressive treatment of brain infections or tumors: To minimize damage and epileptogenesis.
    • Prompt and accurate diagnosis of epilepsy: To initiate appropriate ASM therapy and prevent seizure recurrence and associated injury.
    • Screening for genetic risk factors: In families with inherited epilepsies.
  • Tertiary: Preventing complications and improving outcomes in individuals already diagnosed with epilepsy.
    • Optimal ASM management: Achieve seizure freedom or best possible control with minimal side effects.
    • Education: Patient and family education on seizure first aid, triggers, and medication adherence.
    • Safety measures: Driving restrictions, avoiding hazardous activities during uncontrolled seizures.
    • Management of comorbidities: Screening and treating depression, anxiety, cognitive dysfunction.
    • SUDEP prevention: Counseling on risk factors, maximizing seizure control (especially GTCs), adherence to ASMs, nocturnal monitoring (e.g., seizure alarms) for high-risk patients.
    • Pregnancy planning: Pre-conception counseling to optimize ASM choice and dose, discuss folic acid supplementation (4 mg/day).

Special Populations

  • Pediatric:
    • Etiology: Often genetic or developmental brain abnormalities.
    • Syndromes: Infantile spasms, absence epilepsies, juvenile myoclonic epilepsy, Dravet syndrome.
    • ASMs: Dosing adjusted for weight and age. Valproate use in girls/young women carefully weighed against teratogenicity risk. Phenobarbital use often reserved due to cognitive side effects.
    • Developmental impact: Epilepsy can significantly affect cognitive, behavioral, and social development. Early intervention and neuropsychological assessment crucial.
    • Febrile seizures: Common, usually benign, distinct from epilepsy.
  • Geriatric:
    • Incidence: Highest incidence of new-onset epilepsy.
    • Etiology: Primarily structural (stroke, neurodegenerative diseases, brain tumors, head trauma).
    • ASMs:
      • Polypharmacy: Increased risk of drug-drug interactions with ASMs.
      • Comorbidities: Renal/hepatic impairment, cardiovascular disease, osteoporosis.
      • Side effects: Increased sensitivity to cognitive side effects (dizziness, sedation, ataxia) and hyponatremia (with oxcarbazepine). Start low, go slow.
      • Preferred ASMs: Levetiracetam, Lamotrigine, Gabapentin/Pregabalin usually better tolerated. Avoid phenobarbital, benzodiazepines as chronic ASMs.
  • Pregnancy:
    • Pre-conception counseling: Essential. Discuss risks/benefits of ASMs, optimize treatment to monotherapy at lowest effective dose.
    • ASM choice:
      • Lowest risk: Levetiracetam, Lamotrigine.
      • High risk: Valproate (contraindicated if possible due to high teratogenic risk: 10% risk of major congenital malformations, significantly increased risk of developmental delay/autism spectrum disorder).
      • Folic acid supplementation: 4 mg/day for all women of childbearing potential on ASMs, started at least 3 months pre-conception.
    • Seizure control: Aim for seizure freedom. Seizure frequency may change during pregnancy (up to 30% increase/decrease often due to hormonal changes, ASM level changes, or sleep deprivation).
    • Monitoring: Close monitoring of ASM levels (levels may drop due to increased metabolism and volume of distribution), especially for lamotrigine and levetiracetam.
    • Delivery: Vaginal delivery usually possible. Status epilepticus is a rare but serious complication.
    • Breastfeeding: Most ASMs are compatible with breastfeeding; weigh risks/benefits. Monitor infant for sedation.
  • Comorbidities:
    • Psychiatric disorders: Depression, anxiety, psychosis are common. Screen regularly and treat aggressively. ASMs can sometimes worsen or improve mood (e.g., topiramate may induce depression, lamotrigine may have mood-stabilizing effects).
    • Cognitive impairment: Evaluate and provide support/rehabilitation.
    • Sleep disorders: Insomnia, sleep apnea. Can exacerbate seizures and reduce quality of life; require specific treatment.
    • Migraine: Increased prevalence of migraine in epilepsy patients.
    • Bone health: Screen for and manage osteoporosis. Counsel on calcium and vitamin D supplementation.

Clinical Pearls

  • Diagnostic:
    • A good witness history is paramount: Often more valuable than EEG for initial diagnosis.
    • A normal routine EEG does not rule out epilepsy: Repeat EEGs, sleep deprivation, or V-EEG increase yield.
    • MRI is essential for all new-onset epilepsy: Always look for the underlying cause, especially a structural lesion.
    • Don't misdiagnose PNES as epilepsy: V-EEG is the gold standard for differentiation.
    • Beware of Todd's paralysis: Focal weakness after a seizure strongly suggests focal seizure origin, even if the seizure looked generalized.
  • Treatment:
    • Monotherapy first: Start with one ASM and titrate to efficacy before adding a second.
    • Tailor ASM choice: Based on seizure type, epilepsy syndrome, patient comorbidities, and potential side effects.
    • Inform patients about ASM side effects: Especially skin rashes (lamotrigine, carbamazepine) and teratogenicity (valproate).
    • Emphasize adherence: Missed doses are common causes of breakthrough seizures.
    • For absence seizures, ethosuximide is first-line: Valproate is effective but has greater side effect burden.
    • In status epilepticus, time is brain: Act quickly with benzodiazepines, followed by second-line ASMs.
  • Pitfalls:
    • Over-reliance on EEG: A normal EEG does not exclude epilepsy.
    • Starting ASMs after a single provoked seizure: (e.g., alcohol withdrawal, acute metabolic derangement) without first addressing the underlying cause. Unless there's a high recurrence risk.
    • Underdosing ASMs: Leading to breakthrough seizures.
    • Stopping ASMs abruptly: Can precipitate withdrawal seizures (including status epilepticus).
    • Failing to consider non-epileptic causes of spells: Syncope, PNES, migraine aura, TIA, sleep disorders.
    • Ignoring comorbidities: Especially psychiatric conditions, which significantly impact QoL and adherence.
    • Not discussing SUDEP risk: Important for patient education, especially with GTC seizures.

Recent Updates

  • Guidelines:
    • ILAE 2017 Seizure and Epilepsy Classification: Provides a contemporary framework for diagnosis and management, emphasizing etiology.
    • NICE Guidelines (UK): Regular updates on diagnosis and management of epilepsy in adults and children.
    • American Academy of Neurology (AAN) Practice Guidelines: Updates on specific topics like ASM selection, management of epilepsy in pregnancy, and SUDEP prevention.
  • Evidence:
    • Newer ASMs: Such as cenobamate, perampanel, fenfluramine (for Dravet syndrome), and cannabidiol (for specific rare epilepsies) offer additional treatment options, particularly for refractory cases.
    • Improved understanding of genetic epilepsies: Advances in genetic testing are helping identify specific genetic causes, which can guide personalized treatment (e.g., precision medicine approaches).
    • Advances in neuroimaging: Higher resolution MRI, PET/SPECT/MEG technology improving seizure localization for surgical candidates.
    • Wearable devices for seizure detection: Technology is advancing, offering potential for improved seizure monitoring and potentially reducing SUDEP risk through alarm systems.
  • Controversies:
    • Optimal timing for ASM withdrawal: Still debated, weighing recurrence risk against long-term ASM burden.
    • Role of comprehensive genetic testing: While becoming more accessible, its clinical utility and cost-effectiveness for all patients with epilepsy remains an area of study.
    • Predicting SUDEP: Ongoing research to identify more reliable biomarkers and interventions beyond seizure control.
    • Impact of ASMs on cognitive function and long-term brain health: Active area of investigation, guiding choice of ASMs.

Key References

  • Guidelines:
    • International League Against Epilepsy (ILAE): Official classification papers (e.g., ILAE 2017 Classification of Seizures, ILAE 2017 Classification of the Epilepsies). Available on ILAE website (www.ilae.org).
    • National Institute for Health and Care Excellence (NICE): Clinical Guideline CG137: Epilepsy in adults and children: diagnosis and management. (nic.org.uk)
    • American Academy of Neurology (AAN): Various practice guidelines related to epilepsy (e.g., management of epilepsy in women of childbearing potential, evidence-based guideline for the treatment of convulsive status epilepticus). (aan.com)
    • Epilepsy Foundation: Provides patient and professional resources (epilepsy.com).
  • Studies:
    • SANAD Study (Standard and New Antiepileptic Drugs): Landmark trials comparing efficacy and tolerability of ASMs for focal and generalized epilepsies.
    • MESS Trial (Medical Treatment of Epilepsy in the Elderly Study): Informing ASM use in older adults.
    • RESCUE-SE Trial: Informing acute management of status epilepticus.
  • Reviews:
    • UpToDate: Comprehensive, evidence-based medical information (www.uptodate.com).
    • Harrison's Principles of Internal Medicine / Braunwald's Heart Disease: Standard textbooks for general medical knowledge.
    • Epilepsia, Lancet Neurology, New England Journal of Medicine: Leading journals publishing epilepsy research.

Disclaimer: This information is provided for educational purposes only and should not be considered medical advice. It is essential for healthcare professionals to exercise their independent clinical judgment and consult official guidelines and up-to-date scientific literature when making decisions regarding patient care. The use of specific medications, dosages, and treatment strategies must always be tailored to the individual patient's condition, comorbidities, and preferences.

Dr. Vivek's AI | For Educational Purposes Only